[Correlation between Expression of Peripheral IL-17 Protein and Aggression of Bipolar Mania].
OBJECTIVE
To explore the correlation between the interleukin-17 (IL-17) level of peripheral blood and aggression of bipolar mania.


METHODS
Thirty-six patients of bipolar mania were selected as experimental group by DSM-IV-TR and received treatment with quetiapine and lithium. Thirty-six healthy volunteers with similar age and gender were selected as control group. The level of IL-17 at baseline in each group and the level of IL-17 in the experimental group after treatment for 2, 4 and 8 weeks were detected by ELISA.


RESULTS
The level of IL-17 in experimental group at baseline, after treatment for 2 and 4 weeks were all significantly higher than that in control group. After 8 weeks treatment, there was no significant difference between the two groups (P > 0.05). After 2, 4 and 8 weeks treatment, the total score and aggression score of Young Mania Rating Score (YMRS) were significantly lower than the baseline level (P < 0.05). In experimental group, the level of IL-17 was positively correlated with the two scores of YMRS at baseline (P < 0.05).


CONCLUSIONS
Bipolar mania may be related to the up-regulation of IL-17. The level of IL-17 is related to the severity of manic symptoms at baseline, especially aggression symptom.
Hao-zhe
HZ
Li
Wu
W
Hong
Zuo-wei
ZW
Wang
Cheng-mei
CM
Yuan
Ze-zhi
ZZ
Li
Jia
J
Huang
Chen
C
Zhang
Ning-ning
NN
Li
Zhi-guang
ZG
Lin
Yi-ru
YR
Fang
D000374:Aggression / Q000187:drug effects*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001714:Bipolar Disorder / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D016022:Case-Control Studies; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004311:Double-Blind Method; D006801:Humans; D020381:Interleukin-17 / Q000097:blood* / Q000378:metabolism; D018020:Lithium Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000069348:Quetiapine Fumarate / Q000627:therapeutic use*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D015415:Biomarkers; C508717:IL17A protein, human; D020381:Interleukin-17; D018020:Lithium Compounds; D000069348:Quetiapine Fumarate